Actemra does not meet endpoints in phase III COVACTA study for severe COVID-19 associated pneumonia.- Genentech/Roche

Genentech, a member of the Roche Group announced that the Phase III COVACTA study of Actemra (tocilizumab) did not meet its primary endpoint of improved clinical status in hospitalized adult patients with severe COVID-19 associated pneumonia. In addition, the key secondary endpoints, which included the difference in patient mortality at week four, were not met; however, there was a positive trend in time to hospital discharge in patients treated with Actemra. The COVACTA study did not identify any new safety signals for Actemra. Further analysis of the trial results is needed to fully understand the data. The results will be submitted for publication in a peer-reviewed journal.